<DOC>
	<DOCNO>NCT00575185</DOCNO>
	<brief_summary>This randomize , placebo-controlled , double-blind single-center proof concept study evaluate anti-EBV activity 4 gram valomaciclovir ( 2 gram BID ) 21 day subject infectious mononucleosis document caused primary EBV infection . Otherwise healthy subject ( ≥15 year old ) refer u clinical diagnosis primary infectious mononucleosis screen laboratory-confirmed primary EBV infection enrol .</brief_summary>
	<brief_title>Activity Valomaciclovir Infectious Mononucleosis Due Primary Epstein-Barr Virus Infection</brief_title>
	<detailed_description>Subjects see 2 time week 3 week weekly 3 week . Clinical finding , clinical lab test , EBV viral load , EBV antibody titer obtain clinic visit .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Epstein-Barr Virus Infections</mesh_term>
	<mesh_term>Infectious Mononucleosis</mesh_term>
	<criteria>Age 15 year old Within 14 day initial symptom present illness diagnose health care provider infectious mononucleosis confirm due primary EBV antibody profile . The criterion antibody confirmation primary EBV screen visit : 1 ) Positive antiEBV VCA IgM antibody negative antiEBV EBNA1 IgG antibody ; 2 ) EBV antibody test do Clinical Virology Research Laboratory use commercial ELISA kit ( Diamedix Corporation , Miami , FL ) . Willingness sign Informed Consent Form ( ICF ) Willingness contribute sample blood oral washing regular interval Males female must use effective contraception treatment least 90 day follow treatment Negative pregnancy test result Screening Visit females childbearing potential ( include female bilateral tubal ligation ) . Female patient childbearing potential must willing use approve method doublebarrier contraception ( hormonal plus barrier barrier plus barrier , eg , diaphragm plus condom ) time first dose administration 90 day completion dose male patient female partner childbearing potential must willing use condom . Patients sterile infertile ( define postmenopausal undergone complete hysterectomy ) eligible . Estimated creatinine clearance ( Cockcroft Gault method ) ≥ 60 ml/min Absolute neutrophil count ≥ 1000 cells/microliter Platelets ≥ 100,000/microliter Hemoglobin ≥ 9.5 g/dL Previous history infectious mononucleosislike illness Immunosuppressed due medical disease and/or immunosuppressive immunomodulating medication ( e.g. , corticosteroid prior enrollment , cytotoxic drug , interferon ) Another intercurrent viral infection ( include HIV ) , base history refer physician medical evaluation More 7 day elapse since onset illness ( include screen time ) The following concomitant medication prohibit : probenecid , trimethoprim , myelosuppressive therapy , medication know nephrotoxic Breast feeding study Corticosteroids permit . If prescribe subject 's primary physician treatment acute disease subject enrol , subject replace .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Mono</keyword>
	<keyword>Mononucleosis</keyword>
	<keyword>Epstein-Barr virus</keyword>
</DOC>